argenx Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
$398 million in first quarter global net product sales
FDA review ongoing for CIDP sBLA with PDUFA target action date of..
$398 million in first quarter global net product sales
FDA review ongoing for CIDP sBLA with PDUFA target action date of..
*8.3*
*PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY *
*A PERSON WITH INTERESTS IN RELEVANT SECURITIES..
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing..